Navigation Links
Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
Date:8/12/2009

CHAPEL HILL, N.C., Aug. 12 /PRNewswire/ -- Cempra Pharmaceuticals today announced the appointment of John H. Johnson, Chief Executive Officer of ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to the company's Board of Directors. Mr. Johnson brings more than 25 years of biopharmaceutical executive and operational management experience, including leadership of successful anti-infective businesses and numerous flagship pharmaceutical products, to his role as an independent member of the Board.

"I've been closely tied to the antibacterial and public health product markets throughout my career in the biopharmaceutical industry, and Cempra's clinical-stage anti-infective programs address an absolutely critical market need for safe, potent antibiotics," said Mr. Johnson. "Cempra is at a turning point in the company's development of its two lead compounds, as both are poised to advance into later stage clinical trials. I look forward to working with Cempra's other Board members and management to enable the success of these much-needed drugs."

Cempra's lead macrolide, CEM-101, will soon enter a Phase 2 clinical trial for moderate to moderately severe community-acquired bacterial pneumonia. Cempra has also initiated an adaptive design Phase 2/3 trial in acute bacterial skin structure infections for CEM-102, an antibiotic with an established record of treating staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). Cempra recently completed a $46 million Series C financing that will fund the further development of these compounds.

"John's respected reputation, deep knowledge of the antibacterial market and strong business acumen makes him an extremely well-positioned, highly-valued addition to our Board of Directors," said Prabhavathi Fernandes, President and CEO, Cempra Pharmaceuticals. "Following a very successful financing in May, we're well-funded to continue to move CEM-101 and CEM-102 forward in clinical trials. I am confident that we've assembled the best investors, Board members, and management team with the collective antibacterial market and product strategy experience necessary to deliver against Cempra's business and development objectives."

Mr. Johnson has served as Chief Executive Officer of ImClone Systems since August 2007. He also served as a member of the company's Board of Directors until the company became a wholly-owned subsidiary of Eli Lilly and Company in November 2008. Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group. Earlier in his career, Mr. Johnson held roles of increasing responsibility in Sales and Sales Management at Pfizer before joining Johnson & Johnson to help lead their entry into the anti-infectives business. He advanced through positions of increasing responsibility with Ortho-McNeil, including leading the commercial groups responsible for the development of sales, marketing and new product strategies of several of the company's flagship brands, including LEVAQUIN(R), ULTRAM(R) and TOPAMAX(R). Mr. Johnson also previously served as President and CEO of Parkstone Medical Information Systems. He received a B.S. degree from East Stroudsburg University of Pennsylvania. Mr. Johnson is also a member of the Board of Directors of BioNJ.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing two antibacterials to address critical medical needs. These products, both in clinical trials, address the increasingly urgent need for new treatments that target drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products with consideration of pricing and reimbursement issues throughout the lifecycles of its products. The company is also using its proprietary chemistry technology to develop macrolides without antibacterial activity for uses related to motilin receptor activation, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.


'/>"/>
SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
2. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
3. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
4. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
5. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
6. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
7. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. ADVENTRX Pharmaceuticals Announces Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):